tweenvest

Metis TechBio Co., Ltd. (SEHK: 7666)

Health Care · Biotechnology · CN

HK$8.36

-19.69% today · -64.9% 1Y

Public summary
A free snapshot of Metis TechBio Co., Ltd., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Metis TechBio Co., Ltd. (SEHK: 7666) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.26B and employs 150 people.

Over the last twelve months the share price has lost 64.9%, trading between 8.36 and 29.98.

Tweenvest scores Metis TechBio Co., Ltd. across four factors: quality 49/100, value 67/100. Its strongest factor is value.

7666 price history

May 15, 2026 · 21.70Weekly closes 8.36 – 21.70Nov 13, 2026 · 8.36

Key figures

Market cap
$1.26B
Revenue (TTM)
$38.00M
P/E
-15.33
EPS
-4.63
Dividend yield
—
Beta (5Y)
—
52-week high
HK$29.98
52-week low
HK$8.36
Avg volume (3M)
—
Shares outstanding
1.18B
Employees
150
Next earnings
—

About Metis TechBio Co., Ltd.

Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.

ISIN
CNE100007LD1
Founded
2020
Listed since
May 13, 2026
Exchange
The Stock Exchange of Hong Kong Ltd.
Currency
HKD
CompanyMarket capPriceDay
UroGen Pharma Ltd.NasdaqGM: URGN$1.29B$26.39+1.11%
Mineralys Therapeutics, Inc.NasdaqGS: MLYS$1.28B$14.48-0.34%
Savara Inc.NasdaqGS: SVRA$1.27B$4.72+5.36%
Pacific Shuanglin Bio-pharmacy Co., Ltd.SZSE: 000403$1.26BCN¥8.99-0.66%
Idorsia LtdSWX: IDIA$1.26BCHF3.91-1.06%
Hualan Biological Vaccine Inc.SZSE: 301207$1.25BCN¥14.05-1.75%
BioGaia AB (publ)OM: BIOG B$1.25BSkr125.60+0.24%
Silence Therapeutics plcNasdaqGM: SLN$1.23B$19.83+0.15%

Browse every Biotechnology company →